|
1 Indications & Usage Fosaprepitant For Injection, In Combination With Other Antiemetic Agents, Is Indicated In Adults For The Prevention Of: • Acute And Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Highly Emetogenic Cancer Chemotherapy (Hec) Including High-Dose Cisplatin. • Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Moderately Emetogenic Cancer Chemotherapy (Mec). Limitations Of Use • Fosaprepitant For Injection Has Not Been Studied For The Treatment Of Established Nausea And Vomiting. Pediatric Use Information Is Approved For Merck Sharp & Dohme Corp., A Subsidiary Of Merck & Co., Inc.’s Emend (Fosaprepitant) For Injection. However, Due To Merck Sharp & Dohme Corp., A Subsidiary Of Merck & Co., Inc.’s Marketing Exclusivity Rights, This Drug Product Is Not Labeled With That Pediatric Information. Fosaprepitant For Injection Is A Substance P/neurokinin-1 (Nk 1 ) Receptor Antagonist, Indicated In Adults, In Combination With Other Antiemetic Agents, For The Prevention Of ( 1 ): • Acute And Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Highly Emetogenic Cancer Chemotherapy (Hec) Including High-Dose Cisplatin. • Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Moderately Emetogenic Cancer Chemotherapy (Mec). Limitations Of Use ( 1 ) • Fosaprepitant For Injection Has Not Been Studied For Treatment Of Established Nausea And Vomiting.
|